SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby furnish the details of request for issue of duplicate share certificate reported by shareholder of the Company SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Certificate Under Regulation 40(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 40(10) of the Listing Regulations, please find enclosed Certificate issued by M/s Veenit Pal & Associates, Practicing Company Secretaries, under Regulation 40(9) of the Listing Regulations for the year ended on March 31, 2023 SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanySUN PHARMA ADVANCED RESEARCH COMPANY LTD. 2CIN NO.L73100GJ2006PLC047837 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.05 4Highest Credit Rating during the previous FY AAstable 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)ACUITE RATINGS & RESEARCH LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Dinesh Lahoti Designation: Company Secretary and Compliance Officer EmailId: [email protected] Name of the Chief Financial Officer: Chetan Rajpara Designation: Chief Financial Officer EmailId: [email protected] Date: 21/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Compliance Certificate - Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ("Listing Regulations")
Compliance Certificate as required under Regulation 7(3) of Listing Regulations is attached SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of Share Certificate by the holder SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of Share Certificate SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Clarification - Increase In Volume
Clarification Letter is attached SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Confirmation Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 ['the SEBI (DP) Regulations'] for the quarter ended March 31, 2023 SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Closure of Trading Window
Intimation of closure of Trading Window SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - IT Security Incident
Intimation on IT Security Incident